Chief Executive Officer, Managing Director
Having been recognised for his strategic mindset and meticulous business execution, Dr Wolgen has brought to the Company his international finance experience and professional contacts to European capital markets. As a former equity analyst, his in-depth analysis and expertise of the life science sector has been an asset to CLINUVEL. He held positions in private pharmaceutical companies in Europe, as MD of two medical centres in the UK and Israel, and consulted medical device companies. He has been instrumental in raising $86 million since 2006 for the funding of the current development program of SCENESSE® (afamelanotide 16mg).
Dr Wolgen holds an MBA from Columbia University NY and the London Business School. Trained as a craniofacial surgeon, Dr Wolgen holds an MD from the University of Utrecht, the Netherlands.